Vera Therapeutics (VERA) financial statements
Net income was -$300M.
Free cash flow was -$242M.
The diluted share count rose 19975% over the period (dilution).
Income statement
Fiscal years, from Vera Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $45M | $22M | $69M | $78M | $126M | $215M |
| Selling, general and admin | $4M | $12M | $22M | $24M | $41M | $100M |
| Operating income | -$52M | -$34M | -$91M | -$102M | -$167M | -$315M |
| Interest expense | $166,000 | $20,000 | $992,000 | $4M | $8M | $8M |
| Pre-tax income | -$53M | -$33M | -$89M | -$96M | -$152M | -$300M |
| Income tax | -$1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net income | -$53M | -$33M | -$89M | -$96M | -$152M | -$300M |
| EPS (diluted) | -$166.93 | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 |
| Diluted shares | 0M | 13M | 27M | 43M | 55M | 64M |
Balance sheet
Fiscal years, from Vera Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $54M | $80M | $115M | $161M | $641M | $715M |
| Total current assets | $54M | $83M | $126M | $172M | $651M | $729M |
| Property, plant and equipment | — | $0 | $51,000 | $92,000 | $960,000 | $1M |
| Total assets | $55M | $84M | $131M | $176M | $656M | $735M |
| Total current liabilities | $2M | $8M | $26M | $22M | $25M | $53M |
| Total liabilities | $4M | $14M | $55M | $74M | $79M | $130M |
| Shareholders' equity | -$89M | $70M | $77M | $102M | $577M | $605M |
| Net debt | -$54M | -$80M | -$43M | -$46M | -$93M | -$355M |
Cash flow
Fiscal years, from Vera Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$35M | -$24M | -$68M | -$92M | -$135M | -$241M |
| Capital spending | $99,000 | $0 | $62,000 | $63,000 | $972,000 | $630,000 |
| Free cash flow | -$35M | -$24M | -$68M | -$92M | -$136M | -$242M |
| Stock-based compensation | $331,000 | $3M | $9M | $11M | $21M | $38M |
| Share buybacks (net) | — | — | — | $0 | -$13,000 | $0 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VERA.
Open VERA in InvestinglyQuestions
How much free cash flow does Vera Therapeutics generate?
-$242M in fiscal 2025 (operating cash flow minus capital spending).
From Vera Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.